PF-AtlasКлинические испытания › NCT01079091

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

ADVOS · Не указано

ID реестра
NCT01079091
Фаза
Не указано
Статус
Прекращено
Препарат / вмешательство
ADVOS (Hepa Wash)
Спонсор
Hepa Wash GmbH
Начало
2010-09
Набор участников
14
Центры
1

Об исследовании

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

Открыть NCT01079091 на ClinicalTrials.gov →

Связанные материалы

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT01079091 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.